Sernova Corp.’s Stock Is Buy After Today’s Huge Increase

 Sernova Corp.'s Stock Is Buy After Today's Huge Increase

The stock of Sernova Corp. (CVE:SVA) is a huge mover today! About 158,660 shares traded hands or 6.81% up from the average. Sernova Corp. (CVE:SVA) has risen 6.00% since October 8, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
The move comes after 9 months positive chart setup for the $37.20 million company. It was reported on Nov, 7 by We have $0.43 PT which if reached, will make CVE:SVA worth $25.30 million more.

More important recent Sernova Corp. (CVE:SVA) news were published by: which released: “Sernova Receives Issued Patent in the United States for Its Cell Pouch(TM) and …” on April 23, 2015, also published article titled: “Sernova Announces Appointment of New CFO”, published: “Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance …” on July 12, 2016. More interesting news about Sernova Corp. (CVE:SVA) was released by: and their article: “Sernova and CTI Clinical Trial Announce Regulatory Collaboration” with publication date: November 02, 2016.

Sernova Corp. is a regenerative medicine firm engaged in the research and development of its Cell Pouch and associated technologies, including therapeutic cells. The company has a market cap of $37.20 million. The Firm is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device and protected from immune system attack. It currently has negative earnings. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of serious, chronic diseases, such as diabetes, hemophilia and thyroid disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment